Insiders · CUE

Cameron Gray

Director at Cue Biopharma, Inc. (CUE)

Cameron Gray has filed 3 insider reports with the SEC since February 2021, as director at Cue Biopharma, Inc. (CUE). The latest filing, on June 16, 2022, reports shares withheld for taxes or exercise price and exercise of an in-the-money derivative at Cue Biopharma, Inc. (CUE).

Filings
3
Companies
1
Bought on market
None
Sold on market
None

Companies where Cameron Gray is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Cue Biopharma, Inc. logo
CUE
Cue Biopharma, Inc.
Director687,049$4.76Jun 16, 2022

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Cameron Gray with

Other insiders at the same companies

Questions about Cameron Gray

What is Cameron Gray's role at Cue Biopharma, Inc.?
Cameron Gray reports to the SEC as director at Cue Biopharma, Inc. (CUE), according to the latest filing on June 16, 2022.
How many shares does Cameron Gray own?
After the latest filing that states it, Cameron Gray directly owned 687,049 shares of Cue Biopharma, Inc. (CUE). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Cameron Gray bought or sold stock recently?
No open-market purchases or sales by Cameron Gray are on file. The filings report shares withheld for taxes or exercise price, exercise of an in-the-money derivative, grant or award and gift.
How do I get alerts when Cameron Gray files?
Follow Cameron Gray on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Cameron Gray (SEC CIK 0001590583). Totals count each trade once, skipping amendments whose original is on file, from Feb 1, 2021 on. View on SEC EDGAR